Atossa Genetics (NASDAQ: ATOS) — Perfil da empresa, notícias e dados financeiros
Atossa Therapeutics develops innovative biopharmaceuticals for breast cancer and disorders, focusing on improving women's health outcomes.
Atossa Genetics
Atossa Genetics, now commonly referred to as Atossa Therapeutics (NASDAQ:ATOS), is a biopharmaceutical company focused on developing innovative medicines in the areas of breast cancer and other breast disorders. With a strong commitment to improving women's health, Atossa Therapeutics is dedicated to advancing its pipeline projects, which include proprietary therapeutics and novel methodologies for better drug delivery. The company prioritizes the research and development of solutions that can potentially transform the treatment landscape for patients battling breast cancer, aiming for more targeted and effective therapies. Operating out of its base in the United States, Atossa Therapeutics strives to meet the urgent needs of patients worldwide, aligning its objectives towards breakthroughs that offer hope and improved outcomes in breast health.
Resumo
Operações
Produtos e/ou serviços de Atossa Genetics
- Endoxifen formula designed to reduce mammographic breast density and potential treatment for other conditions related to estrogen.
- Fulvestrant microcatheter technology aiming to directly deliver drugs to the site of breast cancer tumors.
- Oral Endoxifen targeted towards patients who cannot tolerate standard tamoxifen therapy, providing an alternative treatment.
- Preclinical development of CAR-T therapy focusing on innovative approaches to target and eliminate specific cancer cells.
- Studies on proprietary Selective Estrogen Receptor Modulators (SERMs) for potential use in breast cancer and other estrogen-related conditions.
- Development of companion diagnostic tools intended to assist in personalized treatment plans for breast cancer patients.
equipe executiva do Atossa Genetics
- Steven C. QuayChairman, CEO & President
- Mark J. DanielChief Financial Officer
- Janet Rose ReaSenior Vice President of Research & Development
- Delly BehenSenior Vice President of Business Operations
- Richard GraydonInterim Chief Medical Officer
Últimas notícias sobre a Atossa Genetics
Principais indicadores financeiros
Resultados divulgados pela Atossa Genetics, em USD.
- Cap. de mercado
- 23,8 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -4.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -37,1 mi | -34,8 mi | |
| 0 | -27,6 mi | -25,5 mi | |
| 0 | -31,4 mi | -30,1 mi | |
| 0 | -27,7 mi | -26,2 mi |